Fierce Pharma October 27, 2023
Sales of AbbVie and Johnson & Johnson’s leukemia blockbuster Imbruvica are taking a hit from the introduction of BeiGene’s transformative oral treatment Brukinsa.
But what about the impact of the Inflation Reduction Act? In August, Imbruvica was one of the 10 drugs identified by the Centers for Medicare & Medicaid Services (CMS) that will be subject to price negotiations in 2026.
On Friday, as AbbVie presented its third-quarter earnings, the company said that it has recorded a $2.1 billion impairment charge, based on “revised cash flows” for Imbruvica, which drops its carrying value in the United States to $1.8 billion.
“As we calculated the future cash flows, we looked at what we had assumed was a reasonable assumption on the...
Today's Sponsors
Today's Sponsor